Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (334)	10/27/2006 1:05:12 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion: Cloretazine Active As Single Agent In Solid Tumor DOW JONES NEWSWIRES October 26, 2006 8:40 a.m. Vion Pharmaceuticals Inc. (VION) said results from its Cloretazine Phase II trial in patients with small-cell lung cancer suggest the product is active as a single agent in a solid tumor. The New Haven, Conn., pharmaceutical company said the data indicates that Cloretazine warrants further investigation as a potential improvement on treatment options for patients with small-cell lung cancer.